BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed a definitive agreement with the Massachusetts General Hospital (MGH) in Boston, MA to conduct a Phase II clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS).
Posts belonging to Category Technology
While the size of this study is small, the ability of the specific biomarkers used to predict ALS prognosis suggests that the approach holds promise.
Traditionally, ALS patients like Mary would use a BiPAP machine to help her breathe. She’d wear a mask, tethered to a ventilator. It would force air into Mary’s lungs. Now, Mary is the first ALS patient at The Ohio State University to be implanted with a diaphragmatic pacing system to help her strengthen her muscles.
For patients with amyotrophic lateral sclerosis (ALS), the simple act of breathing is often a tough thing to do. Now, these patients have new hope, as a device has been approved by the U.S. Food and Drug Administration (FDA) that may help patients to breathe more easily without a ventilator.
Respiratory failure is one of the major complications associated with amyotrophic lateral sclerosis (ALS). The quest for alternative approaches for treating respiratory failure has led to the study, and subsequent FDA approval, of diaphragm pacing for use in ALS patients.
Please join the Robert A. Stehlin Campaign for ALS (RASCALS) to “Fight ALS One Step At A Time”
on Saturday, Nov. 2nd, Tower Grove Park.
By Kaitlynn Riely for the Pittsburgh Post-Gazette, April 26, 2013 •
A person diagnosed this year with amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig’s disease, will receive basically the same prognosis as the New York Yankee did — an average life expectancy of two to five years.
More than 70 years after Gehrig’s death, [...]
Hoping to stop neuron death in ALS just as they did in Huntington’s, the research team treated mice bred to have an ALS-like disease with injections of melatonin or with a placebo. Compared to untreated animals, the melatonin group developed symptoms later, survived longer, and had less degeneration of motor neurons in the spinal cord.
Data Indicate Initial Clinical Benefit in Overall Clinical and Respiratory Function
NEW YORK, NY and PETACH TIKVAH, ISRAEL, March 21, 2013 — BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, today reported some of the final results from a clinical study evaluating the company’s NurOwn™ technology in 12 ALS patients. NurOwn [...]
“This innovative diaphragm pacing system is an exciting development in the treatment of ALS. It has the potential to improve and extend the lives of hundreds of ALS patients. It is thrilling that our BWH team is able to bring this new treatment to ALS patients in New England,” said Dr. Ducko.